Table 1.

Patient characteristics (n = 60)

Male (n = 38)	63.3%
Female (n = 22)	36.7%
Race
Caucasian (n = 16)	26.7%
African American (n = 25)	41.7%
Hispanic (n = 3)	5.0%
Asian (n = 2)	3.3%
Not listed (n = 14)	23.3%
Mean age ± SD	60.6 ± 6.7
Diabetic (n = 23)	38.3%
Hyperlipidemia (n = 20)	33.3%
Hypertension (n = 42)	70.0%
Treatment
Sofosbuvir/ribavarin/interferon (n = 21)	35.0%
Sofosbuvir/simeprevir (n = 11)	18.3%
Sofosbuvir/ledipesvir (n = 23)	38.3%
Sofosbuvir/ribavirin (n = 4)	8.3%
Sofosbuvir (n = 1)	1.7%
Biopsy stage (n = 49)
1 (n = 8)	13.3%
2 (n = 21)	35.0%
3 (n = 5)	8.3%
4 (n = 15)	25.0%
Statin use (n = 20)	20.0%
Statin held during tx (n = 3)	5.0%
Mean viral load	4746471 ± 7641768
Mean ALT	72.1 ± 56.2
Genotype
1a (n = 30)	50.0%
1b (n = 16)	26.7%
1 undistinguished (n = 9)	15.0%
2 (n = 2)	3.3%
3 (n = 3)	5.0%

ALT: Alanine transaminase.